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Classification Codes), and Disease Count (identified using ICD9 codes). Baseline
model included age, gender and race. Weighted linear regression analyses were
used to risk-adjust PCS and MCS. Model performance was evaluated using adjus-
ted-R squares. RESULTS: According to the MEPS, there were 20.9 million diabetic
patients (unweighted sample 2155) in 2008 with mean age 59.4 (14.2) years. The
mean ( SD) PCS andMCS scores for diabetes patients were 40.51 (0.37) and 48.94
(0.34), respectively. The baseline model (age, gender and race) performance was:
(PCS: R20.0920; MCS: 0.0207). The HRQL-CI explained most of the variation in the
PCS scores (R20.3197). The disease count (R20.2704) and Elixhauser (R20.2679)
explained similar amount of variation in PCS. Unlike PCS, Elixhauser (R20.1865)
performed best in explaining variance in MCS, followed by HRQL-CI (R20.1493)
and Disease count (R20.0905). D’Hoore Index did not perform well in both PCS
(R20.1829) and MCS (R20.0516). CONCLUSIONS: Recently developed HRQL-CI
performed better than other comorbidity measures for risk adjusting PCS; how-
ever, Elixhauser comorbidity measures performed better than HRQL-CI for MCS.
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ADAPTING AND VALIDATING DIABETES SIMULATION MODELS ACROSS
SETTINGS: ACCOUNTING FOR MORTALITY DIFFERENCES USING
ADMINISTRATIVE DATA FROM AUSTRALIA
Hayes AJ1, Clarke PM1, Davis W2
1The University of Sydney, Sydney, NSW, Australia, 2The University of Western Australia,
Fremantle, Australia
OBJECTIVES: To develop age and sex-specific risk equations for predicting mortal-
ity following major complications of diabetes, using a large linked administrative
dataset fromWestern Australia (WA), (n13884 patients) and to incorporate these
into the UKPDS Outcomes Model. To compare the original and adapted models in
predictions of survival and life expectancy followingmyocardial infarction, stroke,
heart failure, amputation and renal failure, and incremental benefits associated
with changes in common risk factors. METHODS: We estimated a multivariate
logistic regression model for the probability of death in the year of a complication,
and a multivariate semi-parametric survival model (Gompertz) for years beyond
the year of the complication. Covariates in the models included the type of com-
plication, comorbidities, sex, type 1 diabetes and age. Using representative input
data and clinical risk factors for Australian patients we ran Monte Carlo simula-
tions of the original and adapted models. Parameter uncertainty was evaluated
using 1000 bootstrapped coefficients of all model risk equations. RESULTS: Simu-
lated survival using Australian mortality equations fell inside the 95% confidence
interval of observed survival, whilst survival using UK mortality equations fell
outside of the interval. The two versions of the model generated differences in life
expectancy following specific events; for example life expectancy of a 74 year old
followingmyocardial infarction was 2.74 (95% CI 2.07-3.42) years for UK versus 4.33
(3.85-4.72) years for WA. However there was little impact of using alternative mor-
tality equations on incremental QALYs gained as a result of reducing Hba1c or
systolic blood pressure, or on aggregate outcomes of life expectancy for a cohort
initially free of complications. CONCLUSIONS: Mortality following major compli-
cations varies across diabetic populations and this can impact on estimates of life
expectancy, but it appears to have less impact on incremental benefits of interven-
tions that are commonly used in pharmacoeconomic analyses.
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ACCOUNTING FOR PSYCHOLOGICAL DETERMINANTS OF TREATMENT
RESPONSE IN HEALTH ECONOMIC SIMULATION MODELS OF BEHAVIOURAL
INTERVENTIONS: A CASE STUDY IN TYPE 1 DIABETES
Kruger J1, Brennan A1, Thokala P1, Cooke D2, Bond R3, Heller S1
1University of Sheffield, Sheffield, UK, 2University College London, London, UK, 3University of
Sussex, Falmer, UK
OBJECTIVES: Health economic modelling has paid limited attention to incorporat-
ing the effects patients’ psychological characteristics can have on the effectiveness
of a treatment. The objective of this study was to test the feasibility of incorporat-
ing psychological prediction models of treatment response within an economic
model of a diabetes structured education programme: Dose Adjustment For Nor-
mal Eating (DAFNE). METHODS: Data from the National Institute for Health Re-
search DAFNE Research Programme were used to support all analyses. Three re-
gression models were used to investigate the relationships between patients’
baseline psychological characteristics and their 12-month HbA1c response to
DAFNE. The regression models were integrated with a patient-level simulation
model of type 1 diabetes to evaluate the cost-effectiveness of two new policies
(providing DAFNE only to predicted responders and offering a follow-up interven-
tion to predicted non-responders) compared with current practice. The model es-
timated costs and quality-adjusted life-years over a 50-year timehorizon fromaUK
National Health Service perspective. Deterministic sensitivity analyses were
conducted. RESULTS: Psychological predictors of treatment response were suc-
cessfully integrated with the health economic simulation model and allowed new
treatment policies to be evaluated. The results suggest that providing DAFNE only
to predicted responders is dominated by current practice (incremental costs
ranged from£297 to £616 and incremental QALYs from–0.112 to –0.209). This result
was insensitive to the psychological prediction model used and to the majority of
sensitivity analysis assumptions tested. The results suggest that providing a fol-
low-up intervention to predicted non-responders dominates current practice. This
result was sensitive to model assumptions. CONCLUSIONS: By collecting data on
psychological variables for a subgroup of patients before an intervention, we can
construct predictive models of treatment response to behavioural interventions
and incorporate these into health economic simulationmodels to investigatemore
complex treatment policies. Further research using this methodology is indicated.
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THE CLINICAL CONSEQUENCES OF EXPOSURE TO CLINICALLY IMPORTANT
DRUG-DRUG INTERACTIONS
Malone DC, Hines LE, Brown S
University of Arizona, Tucson, AZ, USA
OBJECTIVES: To evaluate the clinical and economic consequences of exposure to
potential drug-drug interactions (PDDIs).METHODS: This study was a case-control
study conducted usingMarketScan data from 2004 to 2008. A total of 20 PDDIs were
evaluated. Eligible persons were required to have a new object drug (medication
affected by the interaction claim. For each person the presence of a PDDI (case) was
ascertained using first and last dates of object drug usage overlapped with those
dates for the precipitant drug (medicaition causing the interation). The follow-up
period was 30 days for all PDDIs and 60 days for amiodarone. For each PDDI, cases
were matched one-to-one to controls using unconditional logistic regression with
three variables: age, gender and Charlson score. Matches occurred where the dif-
ference in propensity scores between a case and control was between 0.0001 and
0.01. Medical outcomes were PDDI-pair specific based on a priori defined health
outcomes (using ICD9 codes) occurring during the follow-up period. Logistic and
GLM regression models were constructed to evaluate the presence of negative
medical outcomes and costs, respectively. RESULTS: The total number of case/
control pairs per PDDI of interest ranged from 570 for digoxin/azole antifungals to
128,423 for warfarin/statins. For negative health events, non-significant findings
occurred for only three PDDIs. Among the 17 PDDIs with significant findings, odds
ratios for negative outcomes ranged from 1.67 (95%CI:1.39-2.02) for warfarin/fi-
brates to 12.50 (95%CI:2.96-52.77) for digoxin/macrolide antibiotics. With respect to
total health care costs, higher expenditures occurred among persons with a PDDI
than controls for all 20 PDDIs examined (p 0.001). Cost differences ranged from
$554 for warfin/fibrates to $8814 for digoxin/azole antifungals. CONCLUSIONS: Per-
sons exposed to PDDIs were more likely to experience negative health outcomes
and have higher costs as compared to propensity-score matched controls. PDDIs
are associated with significant morbidity and expense.
PIH2
RELATIONSHIP BETWEEN MUSCLE MASS AND MUSCLE STRENGTH IN THE
ELDERLY POPULATION IN THE UNITED STATES
Chen L, Nelson DR, Zhao Y, Cui Z, Johnston JA
Eli Lilly and Company, Inc., Indianapolis, IN, USA
OBJECTIVES: To characterize the relationship between muscle mass and muscle
strength in the US elderly population, and examine potential sources of population
heterogeneity.METHODS: This study included individuals aged 50 and above from
the National Health and Nutrition Examination Survey (NHANES) 1999-2004 data-
bases. Distributions of muscle mass measured via the height-adjusted appendic-
ular skeletonmusclemass (aASM, in kg/m2), andmuscle strength via the isokinetic
quadriceps strength (IQS, inNewtons)were examined, stratified by age and gender.
The relationship between muscle mass (aASM) and muscle strength (IQS) was
summarized using the partial correlation coefficient adjusting for age and gender.
The effects of individual comorbid medical conditions and body mass index (BMI)
on the relationship between muscle mass and muscle strength were assessed us-
ing a series of multivariable regression models, using survey strata and weighting,
with aASM, age, gender, and each variable of interest (e.g., diabetes) predicting
muscle strength; and with an interaction between aASM and the variable of inter-
est included to assess for effect modification. RESULTS: The study included 5139
individuals with a mean age of 66.2 years and 50.2% female. Mean (SE) aASM was
7.2 (0.03) and declined with age, from 7.6 (0.05) for 50-54 year olds to 6.4 (0.04) for
those 80 and older. Mean (SE) IQSwas 362.3 (2.8), declining from 426.6 (6.7) for 50-54
year olds to 241.6 (6.5) for those 80 and older. aASM and IQS were positively corre-
lated (partial correlation coefficient0.365, p0.0001). Interactions between ASM
and several factors (e.g., diabetes, arthritis and BMI) were statistically significant
(P0.05). CONCLUSIONS: Among individuals aged 50 and above in the United
States,musclemass andmuscle strength are positively correlated. BMI and certain
comorbid medical conditions (e.g., diabetes and arthritis) appear to modify the
effect of muscle mass on muscle strength.
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USE OF MIXED TREATMENT COMPARISON METHODS IN ESTIMATING
EFFICACY OF TREATMENTS FOR HEAVY MENSTRUAL BLEEDING
Hoaglin D1, Filonenko A2, Wasiak R3
1Independent Consultant, Sudbury, MA, USA, 2Bayer Pharma AG, Berlin, Germany, 3United
BioSource Corporation, London, UK
OBJECTIVES: For use in a cost-effectiveness model, synthesize available data to
derive estimates of efficacy for several classes of treatments for heavy menstrual
bleeding (HMB).METHODS: A systematic review identified randomized controlled
trials that reported data onmenstrual blood loss (MBL) at baseline and one ormore
follow-up times. The primary measure of efficacy was the proportion of women
who achieved MBL80mL per cycle (month), as measured by the alkaline hematin
method. Complicating the analysis, some trials reported various summary statis-
tics for MBL, and others used scores from pictorial blood-loss assessment charts
(PBAC). Estimation of the primarymeasure from those diverse data took advantage
of the approximately lognormal distributions of MBL and PBAC scores. Also, re-
ported follow-up times varied substantially. Estimates of efficacy by treatment
class and time were obtained from a Bayesian mixed treatment comparison (MTC)
model. The model also included effects for treatment class, study, and the combi-
nation of treatment class and study and an adjustment for baseline mean MBL.
RESULTS: The evidence network comprised eight treatment classes and 34 ran-
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domized clinical trials (RCTs), with follow-up times from 1 to 36months. Efficacy at
three months of follow-up (estimated as the posterior median) ranged from 87.5%
for the levonorgestrel-releasing intrauterine system (LNG-IUS) to 14.2% for proges-
togens administered for less than twoweeks out of four in themenstrual cycle. The
95% credible intervals for most estimates were quite wide, mainly because of the
limited evidence formany combinations of treatment class and follow-up time and
the uncertainty from estimating %MBL80mL from other outcome data.
CONCLUSIONS: LNG-IUS and endometrial ablation have high efficacy for HMB. The
study yielded useful insights on MTC in sparse evidence networks. Diversity of
outcome measures and follow-up times in the HMB literature presented consider-
able challenges. The Bayesian credible intervals reflected the various sources of
uncertainty.
PIH4
IS SILDENAFIL – APOMORPHINE SUBLINGUAL COMBINATION SIGNIFICANTLY
MORE EFFECTIVE THAN SUBLINGUAL SILDENAFIL IN TREATING ERECTILE
DYSFUNCTION?
Solayman MH1, Badary OA1, Salem KA2, El-Hamamsy M1
1Ain Shams University, Cairo, Egypt, 2Tanta University, Tanta, Egypt
OBJECTIVES: To test the efficacy of a sildenafil (50 mg) and apomorphine (3 mg)
sublingual combination in treatingmale Erectile Dysfunction (ED) in comparison to
sublingual sildenafil (50 mg) that shows an increasing number of non-responders.
METHODS: In all, 50 eligible ED patients were enrolled into a prospective single-
blinded crossover study with two treatment periods, each of 4 weeks, separated by
a 2-weekwashout period. A randomization list in blocks in closed packetswas used
to randomize the patients to receive sildenafil then the combination or the combi-
nation then sildenafil. The primary efficacy endpoint was the percent of attempts
resulting in erection firmenough for intercourse. Other efficacy endpoints included
the percent of attempts resulting in successful intercourse, change in the score of
the 5-item version of the International Index of Erectile Function (IIEF-5) from
baseline, response to Sexual Encounter Profile (SEP) diary questions 2 and 3, and
patient’s preference (Of the two study interventions, which one did you prefer?).
RESULTS: Only 43 patients completed the whole schedule and had results evalu-
able for efficacy. Sildenafil - apomorphine combination had a significantly higher
estimate than sildenafil in regard to the mean percent of attempts resulting in
erection firm enough for intercourse (77.6% vs. 63.1%, p 0.001) and resulting in
successful intercourse (51.1% vs. 34%, p 0.001), as well as erectile function as
evaluated by the change in the median IIEF-5 score from baseline (18 vs. 15 with
baseline of 7, P0.001). Also, the proportion of affirmative answers regarding the
SEP diary was significantly higher after the combination (question 2: 79.1% vs.
55.8% P0.01 and question 3: 65.1% vs. 44.2%, P0.05). At the end of the study,
patient preference was 88.4% for the combination and 4.6% for sildenafil.
CONCLUSIONS: Sildenafil - apomorphine sublingual combinationwas significantly
more effective than sublingual sildenafil in treating ED.
PIH5
SYSTEMATIC REVIEW COMPARING THE EFFICACY OF THE 5-ALPHA
REDUCTASE INHIBITORS (5-ARIS) DUTASTERIDE AND FINASTERIDE IN THE
TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)
Conte T1, Truzzi JC2, Tannus G1, Fonseca M3
1Axia.Bio Consulting, São Paulo, Brazil, 2Federal University of São Paulo, São Paulo, Brazil,
3Federal University of São Paulo / Axia.Bio Consulting, São Paulo, Brazil
OBJECTIVES: Benign prostatic hyperplasia (BPH) is a chronic, progressive disease
with important healthcare and economic implications. 5-alpha reductase inhibi-
tors (5-ARIs), dutasteride and finasteride are effective treatments. If untreated, BPH
may lead to complications such as acute urinary retention (AUR) and the need for
surgery (NfS). The aim of this review is to compare the efficacy of dutasteride and
finasteride in reducing episodes of AUR and the NfS related to BPH. METHODS:
MEDLINE, Lilacs and the Cochrane Central Register of Controlled Trials were
searched (from inception to September 2011) to retrieve randomized clinical trials
(RCTs) and observational studies evaluating these drugs. The search included ar-
ticles published in English, Portuguese, and Spanish. Patients with confirmed di-
agnosis of BPH were included. We analyzed data from studies that reported the
number of AUR or NfS following treatment with dutasteride or finasteride.
RESULTS:The literature search identified 24 potential full-text publications; 9 RCTs
(where 9were duplicates) and 6 observational/ retrospective studies. No RCT head-
to-head comparison was found. Indirect efficacy comparison between the two
5-ARIs, based on RCTs, was deemed inappropriate due to the heterogeneity of the
patients included in the trials, differences in outcomemeasurements, study design
and combination therapies (i.e., alpha blockers) used in the studies. Direct com-
parison of dutasteride and finasteride was available from 3 retrospective cohort
studies, indicating that dutasteridemay bemore effective in reducing the episodes
of AUR (Odds ratio0.79; 95%CI0.68-0.93; p0.0042) and the NfS (Odds ratio0.77;
95%CI0.61-0.98; p0.03) relative to finasteride. CONCLUSIONS: The current evi-
dence on the efficacy of dutasteride and finasteride makes an indirect comparison
between the two 5-ARIs difficult; however, data retrieved from observational stud-
ies indicate improved clinical performance of dutasteride compared to finasteride.
PIH6
ANTIPSYCHOTIC USE AND RISK OF NURSING HOME ADMISSION AMONG
COMMUNITY-DWELLING DUAL ELIGIBLE BENEFICIARIES
Aparasu RR, Chatterjee S
University of Houston, Houston, TX, USA
OBJECTIVES: Antipsychotic agents are often used for behavioral symptoms of de-
mentia and psychoses. This study evaluated the risk of nursing home admission
associated with use of antipsychotics among community-dwelling (Medicare and
Medicaid) dual eligible beneficiaries in the United States. METHODS: The study
involved a retrospective cohort design matched on propensity score using Medi-
care and Medicaid Analytical eXtract (MAX) data from four US states. The study
population included all elderly dual eligible community dwelling beneficiaries
(aged  65 years) who initiated antipsychotics anytime during July 1, 2001 and
December 31, 2003. Antipsychotic users were followed till the occurrence of nurs-
ing home admission or, end of the study period, whichever occurred earlier. The
risk of nursing home admission was modeled using Cox proportional model and
extended Cox hazardmodel stratified onmatched pairs based on propensity score,
using typical agents as the reference category. RESULTS: Analysis of Medicaid-
Medicare community dwelling dual eligible data revealed that there were 88,989
antipsychotic users (47,090 atypical and 41, 919 typical users) in the unmatched
cohort and 60,840 users in the matched cohort (30,420 atypical and 30, 420 typical
users). The unadjusted rate of nursing home admission was 20.58% (6, 260) in the
atypical cohort and 16.15% (4, 914) in the typical cohort. The results of Cox regres-
sion [average HR, 1.29; 95% CI, 1.23 -1.34] as well as extended regression [40days:
HR, 1.15; 1.08-1.23 and40 days: HR, 1.42; 1.33-1.51] suggest that, the risk of nursing
home admission was higher among atypical users compared to typical users.
CONCLUSIONS: The higher risk of nursing home admission among atypical users
compared to typical users may be attributable to indication bias. Since atypical
antipsychotics are often used to control behavioral symptoms of dementia, it is
possible that patients with behavioral symptoms treatedwith atypical agents were
subsequently admitted to nursing homes.
PIH7
RISK OF ALL-CAUSE HOSPITALIZATION IN DUAL ELIGIBLE BENEFICIARIES
USING ANTIPSYCHOTIC AGENTS
Aparasu RR, Chatterjee S
University of Houston, Houston, TX, USA
OBJECTIVES: Previous studies have reported differential safety and efficacy profiles
of typical and atypical antipsychotics in the elderly. The study compared the risk of
all-cause hospitalization among elderly dual eligible beneficiaries (Medicare and
Medicaid) using typical and atypical antipsychotic agents.METHODS: A retrospec-
tive cohort study designmatched on propensity scorewas used to examine the risk
of all-cause hospitalization amongdual eligible beneficiaries 65 years or older using
antipsychotic agents. The study involved use of Medicare and Medicaid Analytical
eXtract (MAX) data from four US states. New antipsychotic users were followed for
up to six months without any censoring. The risk of hospitalization was modeled
using Cox proportional model and extended Cox hazard model stratified on
matched pairs based on propensity score. RESULTS: Analysis of Medicaid-Medi-
care dual eligible data revealed that, therewere 1, 43, 617 newantipsychotic (91, 665
atypical and 51, 952 typical) users in the unmatched cohort and 84, 162 (42,081
atypical and 42,081 typical) users in the matched cohort. The unadjusted rates of
hospitalization were 27.17% and 27.96% among atypical and typical users respec-
tively. Cox hazards regression found that, users of typical antipsychotics were
marginally at a higher average risk of hospitalization compared to atypical users
[Hazard Ratio, (HR), 1.07; 95% Confidence Interval, (CI), 1.04-1.10]. Results of ex-
tended Cox regression suggest that, typical users had a higher risk of hospitaliza-
tion than atypical users within the initial 40 days of therapy [HR, 1.26; 95% CI,
1.21-1.31]. However, the risk of hospitalization decreased with prolonged typical
use [HR, 0.90; 95% CI, 0.86-0.94]. CONCLUSIONS: Overall, typical antipsychotic us-
ers were more likely to experience all-cause hospitalization than atypical users
possibly due to differential safety profiles of antipsychotics. More research is
needed to evaluate specific reasons for the health care impact of antipsychotic use
in the elderly population.
PIH8
MEDICATION USE AND HOSPITAL ADMISSION RATES AMONG PRETERM BORN
INFANTS COMPARED TO FULL TERM BORN INFANTS
Houweling LMA1, Bezemer ID1, Penning FJA1, Van Lingen RA2, Meijer WM1,
Herings RMC1
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Department of
Neonatology Isala Clinics, Zwolle, The Netherlands
OBJECTIVES:About 5-12% of all pregnancies inwestern countries result in preterm
birth. Preterm born infants may be at increased risk of adverse outcomes. This
study compared hospitalization andmedication use in the first year of life between
preterm and full term born infants. METHODS: Data for this study were obtained
from linking the PHARMO database network (including detailed information on
drug dispensing and hospitalization histories) with TheNetherlands Perinatal Reg-
istry (including perinatal medical case records). From this linked cohort, all pre-
term born infants (gestational age 37 weeks) between 2004-2007 were randomly
matched to 4 full term born infants on gender, month and year of birth. All infants
were followed from birth until end of data collection in PHARMO or their first
birthday, whichever occurred first. During follow-up, hospitalization and medica-
tion use was assessed. Cox proportional hazard regression models were used to
estimate the relative risk of hospitalization/medication use among preterms com-
pared to full terms. Population attributable risk percentages (PAR%) were calcu-
lated to estimate the proportion of hospitalization/medication use attributable to
prematurity. RESULTS: Among the 71,607 singletons born between 2004-2007,
4,277 (6%) were born preterm of which 90%were hospitalized at birth, compared to
55% of the full terms. Premature infants were twice more likely to be re-hospital-
ized (RR 2.0; 95%CI 1.9-2.2), specifically for respiratory related diseases. Prematurity
accounted for 6%of respiratory re-admissions. Between the age of 6-12months, the
most frequently used outpatient drugs were antibacterials and drugs for obstruc-
tive airway diseases. Premature infants were 50%more likely to receive respiratory
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